
FTH Stock Forecast & Price Target
FTH Analyst Ratings
Bulls say
Faeth Therapeutics is attractive because PIKTOR’s dual PI3Kα and mTORC1/2 blockade is supported by strong mechanistic and preclinical data showing deeper PAM-pathway suppression than single-node inhibitors, with an all-oral design that avoids the IV burden of comparators. The investment case is further strengthened by early clinical signals: the January 2026 data showed about 14% all-grade stomatitis and 0% grade 3+ stomatitis, while the company ended 3Q26 with $174.8M in cash, providing runway into the YE26 PIK-201 readout. That upcoming ~40-patient endometrial dataset is viewed as a key catalyst because an ORR above 30% with tolerable safety could validate the program in a large, high-unmet-need market and de-risk breast-cancer expansion.
Bears say
Faeth Therapeutics is a clinical-stage biotech with high execution risk because its lead PIKTOR program must prove both meaningful efficacy and acceptable safety in breast and endometrial cancer, yet the cited evidence points to a narrow therapeutic window, trial delays, and the possibility of disappointing FTH-PIK-101 phase 1b/2 results versus Street expectations. The company also faces a crowded and improving competitive backdrop, with strong gedatolisib launch dynamics and other PI3Kα or alternate-modality programs showing clinical benefit, while single-node pathway inhibition has repeatedly been undermined by rapid adaptive resistance and parallel-pathway mutations. Given the added financing burden if clinical or commercial progress falters, and the risk that PIKTOR may fail to gain share or launch successfully, the fundamental outlook remains negative.
This aggregate rating is based on analysts' research of Faeth Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FTH Analyst Forecast & Price Prediction
Start investing in FTH
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Faeth Therapeutics Inc (FTH) Forecast
FTH Analyst Forecast & Price Prediction
Start investing in FTH
Order type
Buy in
Order amount
Est. shares
0 shares